Simply put it down as the market is miss pricing IMU in a big...

Simply put it down as the market is miss pricing IMU in a big way.
Good luck to IMM and there holders , they are probably fare priced at the moment, with one drug.
IMU has not one but two platforms of many drugs, with one platform just about proven, or close too.
The upside here could be massive and IMHO will be. B cell leaders and a viral oncology that could just be the holy grail.
Replimune at a two million market cap, what does that make us ?

And just to repeat myself as other shareholders have many times.
buy outs :
BMS- NEKTAR THERPEUTICS 3.6 billion / 1.8 million upfront
MERCK AND EISAI 5.77 billion / 300 million upfront
MERCK AND ABLYNX 7.1 billion
and i can go on and on. Some of these major buyouts have not got half of what IMU has to offer.
Is this ramping ? No I'm just stating facts.
And the best part of all this , is that IMU are going to save many, many lives, and thats a beautiful thing to be a part of,
even if its just as a shareholder.
PH can not be more clearer, 2021 is going to be a very profitable year.
GLTAH